MARKET

SONN

SONN

Sonnet BioTherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.880
+0.040
+1.41%
After Hours: 2.860 -0.02 -0.69% 19:54 01/26 EST
OPEN
2.810
PREV CLOSE
2.840
HIGH
2.930
LOW
2.770
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
54.60
52 WEEK LOW
2.200
MARKET CAP
49.47M
P/E (TTM)
-0.1045
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sonnet Bio completes SON-080 toxicology study in monkeys with no adverse effects seen
Sonnet BioTherapeutics (SONN) has successfully completed a multiple dose non-human primate ((NHP)) study of SON-080 (low-dose recombinant fully human Interleukin 6, or IL-6).The toxicology study demonstrated a wide safety margin
Seekingalpha · 1d ago
DJ Sonnet BioTherapeutics Sees No Adverse Effects in Study for SON-080
Dow Jones · 1d ago
Sonnet BioTherapeutics Says it Successfully Completed a Non-Human Study of SON-080, Expects to Submit Investigational New Drug Application in 2H 2021
No adverse effects observed at all doses tested Using the results of this study, combined with previously compiled clinical safety data, the Company intends to commence evaluation of human equivalent doses for
Benzinga · 1d ago
Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080
* No adverse effects observed at all doses tested * Using the results of this study, combined with previously compiled clinical safety data, the Company intends to commence evaluation of human equivalent doses for initiating pilot clinical efficacy studies...
ACCESSWIRE · 1d ago
The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 17)
Benzinga · 12/18/2020 12:45
Sonnet BioTherapeutics Files For Mixed Shelf Of Up To $100M
-SEC Filing
SEC Filing · 12/17/2020 13:55
CureVac, Triterras leads premarket losers' pack
Triterras (TRIT) -17%.SCYNEXIS (SCYX) -18% after initiates equity raise of $50M.ADDvantage Technologies Group (AEY) -13% on Q4 earnings release.Uxin (UXIN) -11% on FQ2 earnings release.Anchiano Therapeutics (ANCN) -11%.Sonnet BioTherapeutics Holdings (SONN) -10% on FY earnings release.Zynerba Pharmaceuticals (ZYNE) -8% after
Seekingalpha · 12/17/2020 13:23
Sonnet BioTherapeutics reports FY results
Sonnet BioTherapeutics (SONN): FY GAAP EPS of -$6.96.Cash of $7.35M.Pankaj Mohan, Ph.D., Founder and CEO commented, "This year has been incredibly exciting for Sonnet. We successfully executed our public listing,
Seekingalpha · 12/17/2020 11:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SONN. Analyze the recent business situations of Sonnet BioTherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SONN stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 655.07K
% Owned: 3.81%
Shares Outstanding: 17.18M
TypeInstitutionsShares
Increased
2
3.30K
New
8
150.24K
Decreased
2
2.97K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/President/Chief Executive Officer/Director
Pankaj Mohan
Chief Financial Officer/Treasurer/Secretary
John Cross
Corporate Executive
Richard Adams
Corporate Executive
Rich Adams
Chief Operating Officer
Mark Roberson
Chief Technology Officer
Susan Dexter
Chief Scientific Officer
John Cini
Other
Terence Rugg
Director
Nailesh Bhatt
Director
Albert Dyrness
Director
Donald Griffith
Director
Raghu Rao
  • Dividends
  • Splits
  • Insider Activity
No Data
About SONN
Sonnet Biotherapeutics Holdings Inc, formerly Chanticleer Holdings, Inc., an oncology-focused biotechnology company. The Company is developing targeted biologic drugs with enhanced single or bispecific mechanisms.

Webull offers kinds of Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ:SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.